Retifanlimab for anal cancer in people living with HIV: an analysis from prospective immunotherapy studies with prespecified HIV-focused endpoints☆

ESMO Gastrointestinal Oncology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles